244 completed, 154 recruiting, 151 unknown, 59 terminated. 728 Phase 3, 108 Phase 2.
Follow Head and Neck Neoplasms: new trials by email Literature Review of Head and Neck Neoplasms trials Research Report on Head and Neck Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial Camrelizumab, Nab-paclitaxel, Cisplatin - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 3 | Not yet recruiting | Xuekui Liu | 212 | 2027-01-01 | 2026-11-19 |
| Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Cancer | Phase 3 | Not yet recruiting | Asan Medical Center | 172 | 2026-12-31 | 2026-10-29 |
| A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection SYS6010, SG001, SG001 placebo-mimicking - Esophageal Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 585 | 2026-12-30 | 2026-11-09 |
| A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma SYS6010 combined with Enlonstobart, Tislelizumab combined with chemotherapy - Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 424 | 2026-11-06 | 2026-11-09 |
| SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer Standard of Care (SOC), Experimental drug - Head and Neck Cancer | Phase 3 | Not yet recruiting | University Health Network, Toronto | 288 | 2026-11-01 | 2026-10-20 |
| Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy - Esophageal Cancer | Phase 3 | Recruiting | Ruijin Hospital | 160 | 2026-10-15 | 2026-10-22 |
| A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer ICG-guided sentinel lymph node dissection, ICG-guided systematic lymph node dissection - Esophageal Cancer, Sentinel Lymph Node | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 200 | 2026-10-01 | 2026-08-26 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Enlituo® + Anyouping® + PBC, Placebo-Enlituo + Anyouping® + PBC - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 / Phase 3 | Recruiting | Taizhou Mabtech Pharmaceutical Co.,Ltd | 362 | 2026-09-16 | 2026-10-05 |
| Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy - Squamous Cell Carcinoma of Head and Neck | Phase 3 | Recruiting | Ji Dongmei | 316 | 2026-09-15 | 2026-10-02 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-09-08 | 2026-11-09 |
| A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-09-01 | 2026-09-15 |
| SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC SYS6010, Investigator's Choice of monotherapy - Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 340 | 2026-08-15 | 2026-08-11 |
| A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) HS-20093 for Injection, Irinotecan; Paclitaxel; Docetaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Not yet recruiting | Hansoh BioMedical R&D Company | 494 | 2026-07-31 | 2026-06-02 |
| Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma Toripalimab combined with Nimotuzumab, Nimotuzumab - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 566 | 2026-07-20 | 2026-07-16 |
| A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. BupiZenge 25 mg, Lidocaine viscous 2% - Head & Neck Cancer, Oral Mucositis | Phase 3 | Recruiting | OncoZenge AB | 150 | 2026-07-07 | 2026-10-27 |
| APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma APG-157, Surgery, Radiation/Chemotherapy - Head and Neck Cancer, Head and Neck (HNSCC) | Phase 3 | Not yet recruiting | Aveta Biomics, Inc. | 826 | 2026-07-01 | 2026-07-01 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
Showing 20 of 728. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (176) · Nasopharyngeal Carcinoma (140) · Esophageal Neoplasms (133) · Esophageal Squamous Cell Carcinoma (80) · Oropharyngeal Neoplasms (34) · Thyroid Neoplasms (32) · Mouth Neoplasms (31) · Carcinoma, Squamous Cell (28) · Laryngeal Neoplasms (23) · Nasopharyngeal Neoplasms (23) · Neoplasms (23) · Adenocarcinoma Of Esophagus (21) · Stomach Neoplasms (19) · Hypopharyngeal Neoplasms (16)
Neoplasms by Site (725) · Neoplasms (705) · Neoplasms by Histologic Type (438) · Neoplasms, Glandular and Epithelial (437) · Carcinoma (419) · Stomatognathic Diseases (251) · Carcinoma, Squamous Cell (243) · Otorhinolaryngologic Diseases (221) · Digestive System Diseases (216) · Gastrointestinal Diseases (214) · Otorhinolaryngologic Neoplasms (205) · Digestive System Neoplasms (204) · Gastrointestinal Neoplasms (201) · Pharyngeal Diseases (201)
Cisplatin (210) · Radiotherapy (110) · Fluorouracil (93) · Docetaxel (63) · Paclitaxel (54) · Radiotherapy, Intensity-Modulated (50) · Carboplatin (44) · Cetuximab (44) · Gemcitabine (43) · pembrolizumab (39) · Capecitabine (33) · Drug Therapy (31) · Radiation (25) · Neoadjuvant Therapy (21) · toripalimab (21)
Sun Yat-sen University (82) · Fudan University (20) · Radiation Therapy Oncology Group (17) · Groupe Oncologie Radiotherapie Tete et Cou (14) · Merck Sharp & Dohme LLC (12) · National Cancer Institute (NCI) (11) · Alliance for Clinical Trials in Oncology (9) · Chinese Academy of Medical Sciences (9) · The First Affiliated Hospital of Henan University of Science and Technology (8) · Gustave Roussy, Cancer Campus, Grand Paris (7) · Tianjin Medical University Cancer Institute and Hospital (7) · Zhejiang Cancer Hospital (7) · AstraZeneca (6) · Boehringer Ingelheim (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6)
China (311) · United States (168) · France (115) · Canada (90) · United Kingdom (79) · Germany (69) · Italy (67) · Spain (66) · South Korea (60) · Taiwan (60) · Belgium (57) · Poland (49) · Japan (45) · Brazil (44) · Australia (41)
Jun Ma, M.D. (7) · Ming-Yuan Chen, MD,PhD (6) · Ming-Yuan Chen, MD, PhD (4) · Shegan Gao, Doctor (4) · Tanyou Shan, Master (4) · Xiaozhi Yuan, Master (4) · Zefen Xiao, MD (4) · Dan Wang, Master (3) · Fang-Yun Xie, M.D. (3)
PMID 31150573, PMID 27686945, PMID 28837405, PMID 29584545, PMID 31420360, PMID 35240053, PMID 38507662, PMID 39970442, PMID 41343184, PMID 15128893, PMID 15128894, PMID 16161069, PMID 22749632, PMID 23148692, PMID 24224128, PMID 24371038, PMID 24982463, PMID 25057165, PMID 26805559, PMID 27223606, PMID 27266524, PMID 27567280, PMID 27718784, PMID 27742014, PMID 30089078, PMID 30213452, PMID 30548235, PMID 33492986, PMID 33538338, PMID 33684371, PMID 34111416, PMID 34341578, PMID 35997729, PMID 36746459, PMID 37139963, PMID 37537541, PMID 38710003, PMID 39438442, PMID 40373876, PMID 40511820, PMID 40532178, PMID 40692081, PMID 40890288, PMID 41791006, PMID 42568612, PMID 10640954, PMID 10924966, PMID 10987278, PMID 11212235, PMID 11391598
U10CA180868 (9), 2017 (7), 2019 (7), 2023 (7), 2016 (4), U10CA180820 (4), 2005 (3), 2015 (3), 2025 (3), U10CA021661 (3), 2009 (2), 2014 (2), 2018 (2), P30CA008748 (2), U10CA021115 (2)